Agios Pharmaceuticals Stock Current Valuation
| 8AP Stock | EUR 52.50 1.50 2.94% |
Valuation analysis of Agios Pharmaceuticals helps investors to measure Agios Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Agios Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Agios Pharmaceuticals is based on 3 months time horizon. Increasing Agios Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Agios stock is determined by what a typical buyer is willing to pay for full or partial control of Agios Pharmaceuticals. Since Agios Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Agios Stock. However, Agios Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 52.5 | Real 42.53 | Hype 52.5 | Naive 48.94 |
The real value of Agios Stock, also known as its intrinsic value, is the underlying worth of Agios Pharmaceuticals Company, which is reflected in its stock price. It is based on Agios Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Agios Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Agios Pharmaceuticals helps investors to forecast how Agios stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Agios Pharmaceuticals more accurately as focusing exclusively on Agios Pharmaceuticals' fundamentals will not take into account other important factors: Agios Pharmaceuticals Company Current Valuation Analysis
Agios Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Agios Pharmaceuticals Current Valuation | 1.01 B |
Most of Agios Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Agios Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Agios Pharmaceuticals has a Current Valuation of 1.01 B. This is 92.96% lower than that of the Healthcare sector and 78.24% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 93.92% higher than that of the company.
Agios Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Agios Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Agios Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Agios Pharmaceuticals by comparing valuation metrics of similar companies.Agios Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Agios Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (18.34) % | |||
| Current Valuation | 1.01 B | |||
| Shares Outstanding | 54.94 M | |||
| Shares Owned By Insiders | 1.34 % | |||
| Shares Owned By Institutions | 98.67 % | |||
| Price To Earning | (9.13) X | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 159.36 X | |||
| Revenue | 14.24 M | |||
| Gross Profit | 140.39 M | |||
| EBITDA | (380.48 M) | |||
| Net Income | (231.8 M) | |||
| Cash And Equivalents | 495.39 M | |||
| Cash Per Share | 8.43 X | |||
| Total Debt | 116.47 M | |||
| Debt To Equity | 21.80 % | |||
| Current Ratio | 5.96 X | |||
| Book Value Per Share | 19.13 X | |||
| Cash Flow From Operations | (309.48 M) | |||
| Earnings Per Share | (6.05) X | |||
| Target Price | 62.43 | |||
| Number Of Employees | 25 | |||
| Beta | 0.92 | |||
| Market Capitalization | 1.39 B | |||
| Total Asset | 1.24 B | |||
| Z Score | 6.6 | |||
| Net Asset | 1.24 B |
About Agios Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Agios Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Agios Stock
Agios Pharmaceuticals financial ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharmaceuticals security.